Abstract:Objective:To investigate the diagnostic accuracy and correlation between cerebrospinal fluid biomarkers and 11C-Pittsburgh compound-B (PIB) PET/CT imaging in Alzheimer disease (AD). The optimal cut-off values of cerebrospinal fluid biomarkers are also determined. Methods:The clinical data of 66 subjects who underwent 11C-PIB PET/CT imaging and lumbar puncture at the General Hospital of Northern Theater Command from January 2011 to March 2020 were retrospectively analyzed. The participants included 32 males and 34 females aged 61-82 (71.0±3.4) years and were divided into the AD patient group (n=50) and the healthy control group (n=16) according to established criteria. Enzyme-linked immunosorbent assay was used to detect levels of the cerebrospinal fluid biomarkers α-synuclein (α-syn), β-amyloid (Aβ) 40, Aβ42, t-tau and p-tau. The level ratios of t-tau to Aβ42 (t-tau/Aβ42) and Aβ42 to Aβ40 (Aβ42/Aβ40) were calculated. The receiver operator characteristic (ROC) curve was used to analyze the diagnostic optimal cut-off value, sensitivity, and specificity of the cerebrospinal fluid biomarkers. 11C-PIB PET/CT images were analyzed. The average Aβ deposition standardized uptake value ratio (SUVR) was calculated, and the accuracy and correlation between the two groups of cerebrospinal fluid biomarkers and 11C-PIB PET/CT imaging in the diagnosis of AD were analyzed. The levels of cerebrospinal fluid biomarkers between the two groups was compared by independent-sample t test, and the count data were compared by χ2 test. Pearson correlation coefficients were calculated for correlation analysis, and consistency was determined using the Kappa test. Results:The levels of cerebrospinal fluid biomarkers α-syn, t-tau and p-tau as well as t-tau/Aβ42 in the AD patient group were higher than those in the healthy control group ( t=2.315, 4.001, 2.336, 3.291, all P<0.01), while the Aβ42 level and Aβ42/Aβ40 were lower than those in the healthy control group ( t=-5.443, -3.487, both P<0.05). T-tau/Aβ42 revealed the highest diagnostic accuracy for AD (AUC=0.892, P<0.001), followed by Aβ42/Aβ40 and α-syn (AUC=0.865, 0.795, both P<0.01). The optimal cut-off values of t-tau/Aβ42 and Aβ42/Aβ40 were 0.509 and 0.072, respectively, and the aptimal cut-off value of α-syn was 465 pg/mL. The sensitivities of t-tau/Aβ42, Aβ42/Aβ40, α-syn and 11C-PIB PET/CT imaging for predicting AD were 80.0% (40/50), 76.0% (38/50), 74.0% (37/50) and 78.0% (39/50), respectively. The sensitivities of the first three methods in combination with 11C-PIB PET/CT imaging for predicting AD were 96.0% (48/50), 94.0% (47/50) and 94.0% (47/50), respectively, which were all higher than a single method ( χ2=5.316-7.440, all P<0.05). The combined diagnostic accuracy of t-tau/Aβ42 and 11C-PIB PET/CT imaging was greater than that of a single diagnostic method (93.9% vs. 80.3%, 93.9% vs. 77.2%), and the difference noted was statistically significant ( χ2=5.469, 7.439, both P<0.05). T-tau/Aβ42, Aβ42/Aβ40 and α-syn level were significantly correlated with 11C-PIB PET/CT SUVR ( r=0.555, -0.451, 0.445, all P<0.01). The Kappa value of diagnostic consistencies of t-tau/Aβ42, Aβ42/Aβ40 and α-syn with 11C-PIB PET/CT imaging were 0.769, 0.623 and 0.587, respectively (all P<0.001). Among the criteria considered, t-tau/Aβ42 demonstrated great diagnostic consistency with 11C-PIB PET/CT. Conclusions:T-tau/Aβ42, Aβ42/Aβ40 and α-syn are ideal diagnostic criteria for AD. Combining these parameters with 11C-PIB PET/CT imaging could improve the accuracy of AD diagnosis.

Diagnostic value of dual-tracer PET imaging in Alzheimer's disease

Comparison of dual-biomarker PIB-PET and dual-tracer PET in AD diagnosis

11C-PIB PET and 18F-FDG PET in patients with Alzheimer's disease and amnestic mild cognitive impairment

Multi-Center Study on Alzheimer'S Disease Using Fdg Pet: Group and Individual Analyses

Analysis of PET and MRI in Alzheimer disease and mild cognitive impairment

18F-FDDNP positron emission tomography in differentiating Alzheimer disease and vascular dementia

Visual Assessment Versus Quantitative Assessment of 11C-PIB PET and 18F-FDG PET for Detection of Alzheimer's Disease

Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer’s Disease Progression

The Value of FDG Combined with PiB PET in the Diagnosis of Patients with Cognitive Impairment in a Memory Clinic.

International consensus on the use of tau PET imaging agent 18 F-flortaucipir in Alzheimer’s disease

P1‐408: 18F‐FDG AND 18F‐AV45 POSITRON EMISSION TOMOGRAPHY IN ALZHEIMER'S DISEASE

Dynamic Imaging of Mild Cognitive Impairment with ~(11)C-PIB

Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment

The Association Between Brain Metabolic Biomarkers Using 18F-FDG and Cognition and Vascular Risk Factors, as well as Its Usefulness in the Diagnosis and Staging of Alzheimer's Disease

Progress of Alzheimer′s Disease Research Based on PET Imaging

Current status of PET tracers for the early diagnosis of Alzheimer's disease

PET and MRI Imaging in Alzheimer’s Disease：Potential Mechanisms and Findings

Diagnostic accuracy and correlation between cerebrospinal fluid biomarkers and 11C-PIB PET/CT imaging in Alzheimer disease

Characteristics of glucose metabolism and amyloid deposition by positron emission tomography images in Alzheimer's disease

The Multi-center Study on Alzheimer's Disease Using FDG PET

PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research